0001104659-24-080039 8-K 14 20240716 7.01 9.01 20240716 20240716 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 8-K 34 001-39202 241118604 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 8-K 1 tm2419484d1_8k.htm FORM 8-K
false 0001477845 0001477845 2024-07-16 2024-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 16, 2024

 

  

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 

Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

 

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On July 16, 2024, Annovis Bio, Inc. (“The Company”) issued a press release announcing FDA approval to transition to its new crystal form of Buntanetap for future clinical trials. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits. 

 

The following exhibits are being furnished herewith:

 

(d) Exhibits.

 

Exhibit No.    Description
99.1   Press Release Dated July 16, 2024
104   Cover Page Interactive Data File

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: July 16, 2024 By:

/s/ Maria Maccecchini

    Name: Maria Maccecchini
    Title: President and Chief Executive Officer

 

 

 

 

 

 EX-99.1 2 tm2419484d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap 

 

MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future clinical trials.

 

In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form. The Company conducted comprehensive bridge studies in various solvents and in animals, comparing the old semi-crystalline form with the new crystalline form of buntanetap. Additionally, Annovis developed an innovative large-scale manufacturing process for the new form. This comprehensive data was submitted to the FDA for review.

 

The FDA has now approved the continuation of buntanetap's development using the new crystal form. This positive response allows Annovis to conduct a comparative study between the old and new forms of buntanetap in a small, single-dose, bioavailability study in humans as part of the transition process.

 

About Buntanetap

 

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.

 

About Annovis Bio, Inc.

 

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

 

 

 

 

Investor Alerts

 

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.

 

Forward-Looking Statements

 

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

Contacts

 

Annovis Bio, Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355

www.annovisbio.com

 

Investor Contact

 

Scott McGowan

InvestorBrandNetwork (IBN)

Phone: 310.299.1717

‍IR@annovisbio.com

Investor Website

 

 

 EX-101.SCH 3 anvs-20240716.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20240716_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20240716_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 16, 2024
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 101 Lindenwood Drive
Entity Address, Address Line Two Suite 225
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 875-3192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports anvs-20240716.xsd anvs-20240716_lab.xml anvs-20240716_pre.xml tm2419484d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2419484d1_8k.htm": { "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20240716", "dts": { "schema": { "local": [ "anvs-20240716.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20240716_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20240716_pre.xml" ] }, "inline": { "local": [ "tm2419484d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2419484d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2419484d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-080039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-080039-xbrl.zip M4$L#!!0 ( +M \%BXLU\?+0, .D+ 1 86YV],_T'U:\86AB9IB$F&DB9E2I(6:",%JS7*=D 4Q]%A ZJ%GW';O>:32; M%C@_>_\.J)_WP;;!)<%A4 47S+>;M,].P0T:X2JXPA1S)!D_!0\HC+6%79(0 M<]!@HRC$$BM'&JD*#IURV0>VO87N Z8!X_?M9JX[E#(250@GDXE#V1A-&'\6 MCL]&VPEV))*QR-5*TU+VVXY^382?DP]0_7!R/&V3IP&FG^(6JG3]1X0:N'<; MO';;!]]^/D_EZ/-K[XZBKR]BW.5==]@0]W%T]5CZ4?^2AO2$/\0C!%0SJ*A9 MNKZLO$G%87P RZ62"Y^N6YT$9Z7 ZC0D]'D5W#TY.8&)UT +R&F/AT:Z K6[ MAP3.E967;, 3*B2B_@(^D#EA'GP(4^<"E*R$'J508J !7L()[#L#-H;*H?#E MB@'&PAX@%.7@/A*]1#1S+( %ET6@,BZ#;/D28;$2FKH6"/6;ATZ.152-)1$] MPO14:MS'TK%[I'8KQ"-,Y27CHPO<1W&H4OD=HY#T"0XL(!$?8*G'3$3(QV_J MF6G5?C74:K,RB[9%$5%3FQN427>YREF([U3Z0!_45JT+HMVPP=3=8 $2U*ST M."=G! /<)Y0DP;,][7+$3' MPC8=_:7*=M1 &8B.L&$-DQXMOZDLL)% W"^H%*X))<(BS"514SUW%Z2I$ZGI MW^?" !U'6 #^P\I#U-NUP6Q*&MT<2:V[T5?'%.K@^ MZ!&J;!MTS9=A8]"5'(A#*8QE[Q3FOR-_D4,BLU,2"^T,)(=:0HN6;=7'BKL^ MG;>8R;/8:PA\%E/)7W89A'F*>=BO&[-_ -LUPN#3)N@_!?N&W6,*BL%7C8 ' M4S5U_ -02P,$% @ NT#P6)8CKTW]"@ @(8 !4 !A;G9S+3(P,C0P M-S$V7VQA8BYX;6S-G5UOX[@5AN\+]#]PW9L6&,<3!RV0[&07&4^R,#:;9&// M;-M%L: EQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__;C;4/1" M1)IP=CXZ/OHX0H1%/$[8^GST=3&^6,SF\Q%*,\QB3#DCYR/&1S_^\.<_(?GG MTW?C,;I*"(W/T!<>C>?L@7^/;O"&G*&?"","9UQ\C[YANE5;^%5"B4 SOGFF M)".RH-CQ&?K[T70:H?%X0+W?"(NY^'H_K^I]S++G]&PR>7U]/6+\!;]R\90> M17PSK,)%AK-M6M7VQ_%.$?Z()>SI3?ZUP2I \7BP]VZ7)^4CMM]SMZ\D1 M%^O)]./'X\D_?[E>1(]D@\<)4\W>#0(7ZWUC+QFK3^'@Z/CD^VJ7Q2!_\ M_ @*3LD]>4!Y,\^R_;-$*4T4":-RVZ,@#W8S5(B)BI\PLL89B=6.3M6.CO^A M=O27=\0/<>Z/M!SGR?N.="WR_V([:UM^\^&U'U>J-E[+ M3PV+9)?)"8S$VJ2JHF,$SO>03PQEW57M/&K42]5HSD6[[6IFS.M,272TYB^3 MF"2R[NF)^C!6'_)FR__\,>-R)7"Q2C.!HTS7E#?C?&0IGYB6E/)":%]81#V- M*Q63B,NIZ3D;T^(P%N$/@F^LNRU;S2V%?]!5%5\<%KD+P&A#)DC*MR(B;^J5 MNEOH*)6.-E0JU)**L/'7Q>B'7(-^UZK_?)H<:G'0T7()M-T0EBUEC986-(M= M=;/-E.[E>ED0G6PQ9/:QEB"E<=S!%W+'L=KY%<5KBWVCW%476VWI/FX4!M') M-D=F+U<:I$2^NOD+22.1/*OE?%<[&C+GG6XQV>K[FB8L!-K&8!)J6D\#^SU9 M)VIJ41;4^2U1&SN&,4#O>NCOM&W.!59Q$- ,<0C.%O4@5$5YXNB"L2VF]^29 MBRY\FC+7U-A,FK#4-4$Q8C$&HE%H42'V1,2O6WG&3@3=]T+14KKF K!JHF'( M@J+#[@T$I)+[960I,$L3-8#U0M*6.C_= ,RV3CT,75"< .;@4Y)*[Y>4Q2.A M5-T/P*Q_0+&)7=,"&S9Y:2N#(@:T!S*31Z R)!QL+E_4ZEPNDP8VMJ;W"4_+ M=A<_E3A8A$R' RG*PY"*\T12[39$#T,MI6MZ *LF-X8L*&+LWD!6"CG*]?XA MN63Q($0JG1] #)MV/$I1@' TG?6A(=4^P;A*T@C3PLN5W)9V-,^B=0T(:->$ MI"4,"A3('0A+$:"9R4.\ O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U ,ML* MT7 -SSBPU-E-V1ZSU?U90!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y61%@: MUY:X8@,RIYDPRX-@ 3!E,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I:&H" M(L%J#*#AH,V?*?5"Q$R.3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F 12E& MN1I)N1J:(M=(L&9+3)AJD*" [ &D!'J4:+^DN)Y\!Y*0+U;6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P M]S,>PRN4GBBW4 UJ0A.MSI" !OB$\"L$?JA>"8%3UX!4C5X(>XBCN6! M2LM_KA-&CL'V6[5NZ>JPVV3*(@R()-@=P$^I_* _(!6#;EDHT$S?T-2I?VBF M0Z&9!@W-]#W0+%]Y(-""N6_-7V M<#:H](),VZH5F(,L/%Q:WOI@40%J/:-"?&*2+ZQNQ9W@+PF+X"4S)/<"#&#: M2HVA#0\=N\$^?JH%L8[S.M84B_+>+XF6^1EEFB;M0TRA"0^2IK'>P:50^T3B MCJ<9IO].GCM/Q.UB+WA8#5LA:2C#0\5FKP^8(@;)(!\GUB6NZH:&]54RH]S= M*\ 66X=7@&N%04!@<]1^!;BX>E*(7'>S8E00#(P(S6)GG6PQ5?5QK2R,+FX; M:O5P_KV6&A]?9)7=A=X]<@8_(-"6N.IIR)SN;;,\B!X'3)F]GLM0KO-T-5YE MF$CMPW>MS-G,;MJI)G)=$$3OFFY:T[0N=]R;OXDDDWN>\[G)DDE%K4%#O&8L%I$B59PM:_R)-/D6!;JVPB5T# !C4- M;440*("V3 X.0J25CB&X$T1!2&1'Y"\!JL1"XO;AP3K;=XE=0=%O6,,!*X. MI->>"8L,&$>U"%2$H#S&+S;S--T2\29X+"&>$ +- R"U]"'B!)GLA:H(],G6 M@D1;.3_NCZ>K99)1V\EE6^)L3@+,53.241X$&X IDX6\#/$'=#S]Z^IO2$O+W^AK3T/^Y2YZE*8(\$*"7>9ZZ+>9-(?_NB8( M!#J,M4Y*2BG26A\O)!RFK'7_(F#M;1&P[ED$K$-K=%BA Y M+MVN:++&0'+"3K5K*#HLFWQ8I$&A OL#QXPJ!!UB7&>TS%.D; MIUN689&_2RYL(Q.@P/9" M$96G+T-24H>R3H MLOP9NGHF^*(>7[\T$D7JA8AB5D MBD ZQ#$UMY)A43^/RTW,,[(!WW;H#W%%T%#SFJ,^?1 T#31I,I6'-4^N\T"D M(GUF,ZHGMX>7> V1XY6QQ:"Q,*XI@F $M 4MB^N_%> G=]YV19/HBG(,7V5I M:!QGS&O;,Y+E'00!$=!V!:7(RX4H5WKI_\^8/8GM&- XR9#1T1 Z VP"=UPR"-1'OH!%<&H%NWI_"P] M9 $D\>?]/7D@0KUWL"2[[+/%;W4*G>BFJ M5X!6ZAFQL@KTNZH$Y;78?K^\ONE:?I*;]2;YUPJG1&[Y+U!+ P04 " "[ M0/!8-DH3CUD' #95P %0 &%N=G,M,C R-# W,39?<')E+GAM;,V<77/: M.!2&[W=F_X.7O28$Z+:;--E.2D.':=ID0]KN[DU'V (TD25&D@/\^Y5L3/FP MY),;G^0B(>;5Q_L<6_:Q)5^\6Z4\>J)*,RDN6]V3TU9$12P3)F:7K:_C]M5X M,!JU(FV(2 B7@EZVA&R]^^O77R+[<_%;NQT-&>7)>?1!QNV1F,JWT1>2TO/H M(Q54$2/5V^@;X9G;(H>,4Q4-9+K@U%#[1='P>?3'2:\71^TVH-YO5"12?;T? M;>N=&[/0YYW.Q3&$5C@TQF=[6=KHZW?P4Q2\X$X_G[M>$ M:!I97D*?KS2[;+EV-\TN^R=2S3J]T]-NYY_/-^-X3E/29L)QBVFK+.5JJ2K7 M/3L[Z^3?EM(CY6JB>-E&OU-V9UNS_98%]#L]T>Q=AKFXF\"O=? MNY2UW:9VM]?N=T]6.FF5\'."2G)Z3Z>1^VNCMVV5"!LSIB=,NI!UW->=@;2[ MI.UK7G"NZ/2R1<23MO7W7IV^Z;YVM?^^)S+KA=TU-7-[5BOJ[+6\4%1387*S M-W;#7A&Z,G:'HDE9D6L?WC?#C)-O=IANU'9[5Y;:UNS'0KGI2MD9+N.]]KF+ M@CPP6^[1.6M-XY.9?.HDE%GFO;[[X$CT\$ZWCDWBLZ"*%M1 M.YXSOHWS5,G41V=#0GHZN@O*-M$,S2O;?N+Z,.1D5HWS0 +DV<4 6ND&B^@' MJF/%%HY+#=@])9!O#Y5OA;>&,9?'SCV=,==?UQ5WRJ5N8WA<\!0!@N]CCA1! MMT@1N!(B(_R>+J2J ;^O!/)^AJ%A\W#L*'EHKB.EJM3E,SG=2&\+_8XNZ*\EJ/90Y8N(:,MKT#<8B[NZFA6\JT8$$RAJZ8'7 M3276WD-_YVOP##:48?701L,8ORMF; \&,DTSL;E'XWDJYI%"\:*D?T%[#:,> M2\YB9IB8?;97B(H17LVY2@>%C)+L^8TU3/A.41=I:B^[\WE<;JV!NIU.?2-O M2 \ECI+KU1O%)3_2.J/JN?PK2D&C@)+V04TW/<[0.+/#WKK;FSRX%3.>4>9( M!66-DO+Y3#7,]HM\4,2MUQNOTXGD_N4AE4(H890$+V"M8R"!@D7) M["KM((T)UZMX3L2,^FU$R/I\I)+;%W'![ M1-U..)L1_TJR8 'P.AM,X@&K3:_?RY?\N)7<*LW[,;0?JK%[I%#@.$LD0_:: M1ITES-"DZ-*0"2)BFU)MU[5YLO/Z4M X*RA!)I&N;W_G7+^2*10YXK-#CSV(N*\$%#SB0\2P6:3Y:8:Z/K,G^H$8LNEAB+^O!)0_X@/%L%FT^?-J M8$\\,QE^9GX@A-)&G I;:0T%\C@EG+_/-!-4!\>6 R$4,N*PF4A1GTD.YHRZL]!MMF/RMF5.U>_V4=V9D\[;0I(?Z4M HH*2K M4-,XY]:=E?S!4^N>#LH;,3&M,H:S9BJ;T]:U?BRK+?^15] M.7>?K6L$D@#R4#F+EXH/4,!Q9KZXFJ2!UI!D.D%@?OVMS@,(21 1'??<,\M1 M25>JJZKKW9UX_)_I2$7/A)E4UT[^%I/"WXAHLJY0;7#R=[E3;33^_D\I=CRT M Q -?,D/K0LHYA*32:3Y"2=U-D@)18*A=24P\0=H.(T%$X2!#'U[?JJ(P_) M"">H9EI8D\G\)I5J3]'X^>@28L@E!2DB'2T@2)I%]B.!SQKEU$:R4 M8HC_.[:HI9+2<$0LCCB)!?H[I\TF\JFL6T:Q$=V: L&7GTTG<(E,K M99M@"NY*.2B/_R>10*>4J$H1=8AUA)IX1(IHJDR/4*-F__(@2-6'N\Y?4NVL M7+Z!'YP!E$AL>'.Z_,"Y?/!S]^!QMSFB3'U^TQ9W9PL/!!0+R(>O\HAH"ORW M3E4\>.ACU22OP)19PE378!EF54#%L-K0%#*])+,' =Q8)I?+9[*;HSVL@)!K M#^*#ZQ$<_'#I%2BDA\X0,V(^2 ^V_W-PF/:U5Z"I<4IN7%3I $%1N'NZ,D.F M-5/)2;P/6E=$HF!8J$M' -$D$]361U@[<"X

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end XML 16 tm2419484d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2024-07-16 2024-07-16 iso4217:USD shares iso4217:USD shares false 0001477845 8-K 2024-07-16 ANNOVIS BIO, INC. DE 001-39202 26-2540421 101 Lindenwood Drive Suite 225 Malvern PA 19355 484 875-3192 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true false